TIDMGSK
RNS Number : 2361N
GSK PLC
30 May 2022
Issued: 30 May 2022, London UK - LSE announcement
GSK announces further appointments to Designate Haleon Board
Demerger and listing of Haleon expected in July 2022
GSK plc (LSE/NYSE: GSK) has today announced the appointments of
Asmita Dubey, Marie-Anne Aymerich and Bryan Supran to the Designate
Haleon Board, the new independent company to be formed following
the demerger of the GSK Consumer Healthcare business, expected in
July 2022.
These appointments follow the appointment of Sir Dave Lewis as
Non-Executive Chair Designate in December 2021 and the appointment
of six directors in March 2022 and complete the formation of the
Designate Haleon Board. This Board will benefit from an appropriate
mix of skills, experience, and diversity to support Haleon as a
listed company.
Sir Dave Lewis, Non-Executive Chair Designate, Haleon, said: "We
are delighted to be welcoming Asmita, Marie-Anne, and Bryan as
Non-Executive Directors to the future Haleon Board. Together they
bring a strong understanding of the global consumer sector, as well
as relevant innovation and Asia experience. These appointments now
complete the Designate Board ahead of the demerger of Haleon from
GSK in July 2022. I look forward to working with our new board
colleagues."
Notes to Editors:
Creation of a new global-leading company in Consumer
Healthcare
The separation of GSK Consumer Healthcare, to form Haleon, is
subject to approval from shareholders and will be by way of a
demerger of at least 80% of GSK's 68% holding in the Consumer
Healthcare business to GSK shareholders (the Consumer Healthcare
business is a Joint Venture between GSK plc (GSK) and Pfizer, Inc.
(Pfizer), with GSK holding a majority controlling interest if 68%
and Pfizer holding 32%). Haleon shares are expected to attain a
premium listing on the London Stock Exchange with American
Depositary Receipts listed on the New York Stock Exchange.
Haleon is strongly positioned to deliver better everyday health,
sustainable above-market growth, and attractive returns to
shareholders.
You can find out more here:
https://www.gsk.com/en-gb/investors/a-new-consumer-healthcare-company/
Further to today's announcement, the complete Designate Haleon
Board is as follows:
-- Sir Dave Lewis**, Non-Executive Chair
-- Brian McNamara, Chief Executive Officer
-- Tobias Hestler, Chief Financial Officer
-- Marie-Anne Aymerich*, Non-Executive Director
-- Manvinder Singh (Vindi) Banga*, Senior Independent Non-Executive Director
-- Tracy Clarke*, Non-Executive Director
-- Dame Vivienne Cox*, Non-Executive Director
-- Asmita Dubey*, Non-Executive Director
-- Deirdre Mahlan*, Non-Executive Director
-- Bryan Supran*, Non-Executive Director (Pfizer nominee)
-- John Young*, Non-Executive Director (Pfizer nominee)
* Indicates those persons who will become directors on
Admission.
**Sir Dave Lewis was appointed as a director of the company on
23 May 2022. His appointment as Non-Executive Chair takes effect on
Admission.
Appointment and selection process
An extensive search and selection process has been conducted for
Non-Executive appointments, including use of an external search
firm, which is a signatory of the Voluntary Code of Conduct for
Executive Search Firms. The external search firm provided a diverse
list of candidates who were approached, evaluated, and interviewed,
against an agreed set of criteria, to identify the most suitable
candidates for appointment.
Asmita Dubey and Marie-Anne Aymerich are expected to be
determined to be independent Non-Executive Directors of Haleon.
Bryan Supran has been nominated by Pfizer and will become a
Non-Executive Director.
Each Non-Executive Director will have a Letter of Appointment
and details of their fees will be provided in the Prospectus
published before demerger.
All appointments announced today will become effective from the
demerger.
Biographical details
Asmita Dubey
Asmita has over 25 years of experience working in consumer
businesses. She has worked at L'Oréal Group (L'Oréal) since 2013
and is currently Chief Digital and Marketing Officer and a member
of the L'Oréal Executive Committee. Asmita brings extensive
expertise of marketing in the digital age and is leading L'Ore al
on a digital transformation journey to evolve the marketing models,
adopt new data-driven solutions, and accelerate emerging business
models for the largest beauty company in the world. Asmita also
brings strong experience working in China where she strengthened
L'Ore al's digital footprint in the region, built L'Ore al's first
joint-business partnerships with Alibaba Group and Tencent Holdings
Ltd and established a broader start-up ecosystem. In addition to
her executive career, Asmita served on the GSK Consumer Healthcare
Digital Advisory Board.
Marie-Anne Aymerich
Marie-Anne has had a successful 30+ year international career
spanning the consumer and luxury sectors, growing businesses, and
shaping brands through innovation and creativity. Most recently,
Marie-Anne led the worldwide Oral Care category at Unilever PLC
where she developed a portfolio of new premium brands. Prior to
that Marie-Anne was Brand General Manager of LVMH Group's (LVMH)
Dior Perfume and Beauty business where she was responsible for
strategy, brand equity, innovation, advertising, and digital.
Before joining LVMH, Marie-Anne was Managing Director for
Unilever's Home and Personal Care business in France. Marie-Anne is
a non-executive director of Pierre Fabre Group and is a Trustee of
The Academy of Saint Martin in the Fields.
Bryan Supran
Bryan brings considerable corporate, strategic and business
development experience from over 25 years as a leading corporate
and transactional attorney across consumer healthcare,
pharmaceutical and life sciences. Since 2015, Bryan has served as
Senior Vice President & Deputy General Counsel of Pfizer, a
role that includes counselling management and the Board of
Directors on strategic initiatives and business development
transactions, such as Pfizer's COVID-19 vaccine collaboration with
BioNTech SE, the successful split-off of its animal health business
as Zoetis Inc., and the joint venture with GSK (of which he is a
director) to create the premier global consumer healthcare business
that will become Haleon. Bryan's role also has included leadership
of Pfizer's intellectual property and international legal teams, as
well as legal support for Pfizer's R&D and manufacturing
organizations. Previously, Bryan practiced law at Ropes & Gray
LLP in Boston and New York, where he helped establish the firm's
life sciences practice.
About GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us .
GSK enquiries:
Media enquiries: Tim Foley +44 (0) 20 8047 (London)
5502
Kathleen Quinn +1 202 603 5003 (Washington
DC)
Analyst/Investor Nick Stone +44 (0) 7717 618834 (London)
enquiries:
James Dodwell +44 (0) 20 8047 (London)
2406
Mick Readey +44 (0) 7990 339653 (London)
Josh Williams +44 (0) 7385 415719 (London)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Sonya Ghobrial +44 (0) 7392 784784 (Consumer)
Emma White +44 (0) 7823 523562 (Consumer)
Rakesh Patel +44 (0) 7552 484646 (Consumer)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASDWSASEESELI
(END) Dow Jones Newswires
May 30, 2022 05:00 ET (09:00 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024